Next-Generation Sequencing for HER2 Status in Breast Cancer: Comparison with Immunohistochemistry and in situ Hybridization by 2018 Focused Update

被引：0
|
作者：
Mooney, Kelly [1 ]
Stehr, Henning [1 ]
Kunder, Christian [2 ]
Zehnder, James [2 ]
Allison, Kimberly [2 ]
Lin, Chieh-Yu [3 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[3] Washington Univ, Sch Med, St Louis, MO USA
来源：
LABORATORY INVESTIGATION | 2019年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
216
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Next-Generation Sequencing for HER2 Status in Breast Cancer: Comparison with Immunohistochemistry and in situ Hybridization by 2018 Focused Update
    Mooney, Kelly
    Stehr, Henning
    Kunder, Christian
    Zehnder, James
    Allison, Kimberly
    Lin, Chieh-Yu
    MODERN PATHOLOGY, 2019, 32
  • [2] Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization:: Comparison with immunohistochemistry
    Kounelis, S
    Kapranos, N
    Malamos, N
    Kouri-Bairaktari, E
    ANTICANCER RESEARCH, 2005, 25 (2A) : 939 - 946
  • [3] HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
    Morsberger, Laura
    Pallavajjala, Aparna
    Long, Patty
    Hardy, Melanie
    Park, Rebecca
    Parish, Rebecca
    Nozari, Azin
    Zou, Ying S.
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [4] HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
    Laura Morsberger
    Aparna Pallavajjala
    Patty Long
    Melanie Hardy
    Rebecca Park
    Rebecca Parish
    Azin Nozari
    Ying S. Zou
    Cancer Cell International, 22
  • [5] HER2 Amplification by Next-Generation Sequencing in Lung Carcinoma: A Comparison of NGS Amplified and Non-amplified Cases by Immunohistochemistry and In Situ Hybridization
    Kivrak, Hale
    Ozakinci, Hilal
    Karasoy, Duru
    Sak, Serpil Dizbay
    BALKAN MEDICAL JOURNAL, 2022, 39 (01) : 21 - 29
  • [6] Comparison of DNA sequencing, immunohistochemistry, and in-situ hybridization techniques to determine HER2 status in metastatic breast cancer patients.
    Lal, Lincy S.
    Milne, Dana
    Walker, Mark S.
    Kovach, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Assessing HER2 status in breast cancer through next-generation sequencing of circulating tumor cells
    Di Cosimo, Serena
    Silvestri, Marco
    De Marco, Cinzia
    Reduzzi, Carolina
    Folli, Secondo
    De Santis, Maria Carmen
    Cappelletti, Vera
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2024, 39 (02): : 184 - 185
  • [8] Breast Cancer HER2 (ERBB2) Status by Next-Generation Sequencing Compared to Traditional Methods
    Russell, Meaghan K.
    Pantazi, Angeliki
    Lyle, Stephen
    Tse, Julie Y.
    MODERN PATHOLOGY, 2018, 31 : 103 - 103
  • [9] Breast Cancer HER2 (ERBB2) Status by Next-Generation Sequencing Compared to Traditional Methods
    Russell, Meaghan K.
    Pantazi, Angeliki
    Lyle, Stephen
    Tse, Julie Y.
    LABORATORY INVESTIGATION, 2018, 98 : 103 - 103
  • [10] HER2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization
    Shirsat, Hemlata S.
    Epari, Sridhar
    Shet, Tanuja
    Bagal, Rajani
    Hawaldar, Rohini
    Desai, Sangeeta B.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2012, 55 (02) : 175 - 179
12345